Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro

References

• Abdul Razak AR, Soulieres D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, et al. 2013. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 24(3):761–769.
   PubMed Web of Science ®Google Scholar
• Belgin S, Altıntop MD, Radwan MO, Özdemir A, Otsuka M, Fujita M, Ciftci   2019. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Eur J Med Chem. 182:111648–111681.
   PubMed Web of Science ®Google Scholar
• Bello CL, LaBadie RR, Ni G, Boutros T, McCormick C, Ndongo MN. 2012. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol. 69(4):991–997.
   PubMed Web of Science ®Google Scholar
• Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, et al. 2012. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 130(10):2445–2454.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang J, Giri N, Hu P. 2018. Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 48(5):459–466.
   PubMed Web of Science ®Google Scholar
• Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC. 2017. Application of static modeling -in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies. Drug Metab Dispos. 45(3):260–268.
   PubMed Web of Science ®Google Scholar
• Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. 2013. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France. Eur J Clin Pharmacol. 69(4):885–888.
   PubMed Web of Science ®Google Scholar
• Darbalaei S, Zhang X, Wang N, Qin Y, Han X, Rang Y, Zhai X, Lu Y. 2018. Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. Pharmazie. 73(6):329–334.
   PubMed Web of Science ®Google Scholar
• Giri N, Masters JC, Plotka A, Liang Y, Boutros T, Pardo P, O’Connell J, Bello C. 2015. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs. 33(4):931–941.
   PubMed Web of Science ®Google Scholar
• Kaza M, Karaźniewicz-Łada M, Kosicka K, Siemiątkowska A, Rudzki PJ. 2019. Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse? J Pharm Biomed Anal. 165:381–385.
   PubMed Web of Science ®Google Scholar
• Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, et al. 2017. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 106:76–82.
   PubMed Web of Science ®Google Scholar
• Kim E, Kim H, Suh K, Kwon S, Lee G, Park NH, Hong J. 2013. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 27(11):1183–1195.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee E, Park K, Jung HH, Park WY, Lee KH, Sohn J, Lee KS, Jung KH, Kim JHm, et al. 2019. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. Int J Cancer. 145(6):1669–1678.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin S, Kim S, Bulitta JB, Weon KY, Joo SH, Ma E, Yoo SD, Park GY, Kwon DR, et al. 2017. Alterations in pharmacokinetics of gemcitabine and erlotinib by concurrent administration of Hyangsayukgunja-Tang, a gastroprotective herbal medicine. Molecules. 22(9):1515–1528.
   PubMed Web of Science ®Google Scholar
• Kim TY, Han HS, Lee KW, Zang DY, Rha SY, Park YI, Kim JS, Lee KH, Park SH, Song EK, et al. 2019. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. Gastric Cancer. 22(6):1206–1214.
   PubMed Web of Science ®Google Scholar
• Kim TM, Keun-Wook L, Do-Youn O, Jong-Seok L, Seock-Ah I, Dong-Wan K, Sae-Won H, Yu Jung K, Tae-You K, Jee Hyun K, et al. 2018. Phase 1 Studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors. Cancer Res Treat. 50(3):835–842.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim Y, Lee S, Yang H, Kim S. 2019. Personalized prediction of acquired resistance to EGFR-targeted inhibitors using a pathway-based machine learning approach. Cancers. 11(1):45–58.
   PubMed Web of Science ®Google Scholar
• Kimura K, Takayanagi R, Fukushima T, Yamada Y. 2017. Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment. Med Oncol. 34(10):178.
   PubMed Web of Science ®Google Scholar
• Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, et al. 2018. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study. Lung Cancer. 126:72–79.
   PubMed Web of Science ®Google Scholar
• Leong S, Moss RA, Bowles DW, Ware JA, Zhou J, Spoerke JM, Lackner MR, Shankar G, Schutzman JL, van der Noll R, et al. 2017. A Phase I dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with erlotinib in patients with advanced solid tumors. Oncologist. 22(12):1491–1499.
   PubMed Web of Science ®Google Scholar
• Ma JS, Wang SH, Huang XL, Geng PW, Wen CC, Zhou YF, Yu LS, Wang XQ. 2015. Validated UPLC-MS/MS method for determination of hordenine in rat plasma and its application to pharmacokinetic study. J Pharm Biomed Anal. 111:131–137.
   PubMed Web of Science ®Google Scholar
• Marques LM, da Silva EA, Jr, Gouvea DR, Vessecchi R, Pupo MT, Lopes NP, Kato MJ, de Oliveira AR. 2014. In vitro metabolism of the alkaloid piplartine by rat liver microsomes. J Pharm Biomed Anal. 95:113–120.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2(6):875–894.
   PubMed Web of Science ®Google Scholar
• Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, et al. 2011. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 302(2):155–165.
   PubMed Web of Science ®Google Scholar
• Noh YH, Lim HS, Jung JA, Song TH, Bae KS. 2015. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 75(1):97–109.
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee KW, Cho JY, Kang WK, Im SA, Kim JW, Bang YJ. 2016. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. Gastric Cancer. 19(4):1095–1103.
   PubMed Web of Science ®Google Scholar
• Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, et al. 2018. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int J Cancer. 143(12):3240–3247.
   PubMed Web of Science ®Google Scholar
• Peters S, Zimmermann S, Adjei AA. 2014. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 40(8):917–926.
   PubMed Web of Science ®Google Scholar
• Qin X, Lu J, Wang P, Xu P, Liu M, Wang X. 2017. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Biochem Pharmacol. 143:129–139.
   PubMed Web of Science ®Google Scholar
• Qiu X, Lin Q, Ning Z, Qian X, Li P, Ye L, Xie S. 2019. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS. J Pharm Biomed Anal. 166:66–70.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Jänne PA, Mok T, O’Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, et al. 2014. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 15(12):1369–1378.
   PubMed Web of Science ®Google Scholar
• Romero D. 2018. Poziotinib for uncommon ERBB mutations. Nat Rev Clin Oncol. 15(7):404–404.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia A, Giri N, LaBadie RR, Ni G, Boutros T, Richie N, Kocinsky HS, Checchio TM, Bello CL. 2014. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. J Clin Pharmacol. 54(5):555–562.
   PubMed Web of Science ®Google Scholar
• Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. 2013. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 17(3):165–184.
   PubMed Web of Science ®Google Scholar
• Wang SH, Wu HY, Geng PW, Lin YY, Liu ZZ, Zhang LJ, Ma JS, Zhou YF, Wang XQ, Wen CC. 2016. Pharmacokinetic study of dendrobine in rat plasma by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 30(7):1145–1149.
   PubMed Web of Science ®Google Scholar
• Wang SH, Wu HY, Huang XL, Geng PW, Wen CC, Ma JS, Zhou YF, Wang XQ. 2015. Determination of N-methylcytisine in rat plasma by UPLC-MS/MS and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 990:118–124.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Wang SH, Lin FY, Zhang QW, Chen HL, Wang XC, Wen CC, Ma JS, Hu LF. 2015. Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 983–984:125–131.
   PubMed Web of Science ®Google Scholar
• Yu X, Zhao X, Zhang J, Li Y, Sheng P, Ma C, Zhang L, Hao X, Zheng X, Xing Y, et al. 2019. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension. Eur J Pharmacol. 850:97–108.
   PubMed Web of Science ®Google Scholar